Papers/PMID:33050029
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.
Nutrients2020The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
(-)-epigallocatechin 3-gallate — decreases body mass
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1“As indicated in Figure 1, EGCG treatment reduced body weight by 10% and gonadal WAT (gWAT) mass by 20%.”
Quoted verbatim from Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.. - Study
- animal · not in humans
- Duration
- 14 days
- Dose
- 20 mg/kg/day by oral gavage for 2 weeks
- Population
- Male C57BL/6 mice fed a high-fat diet for 8 weeks, then treated with EGCG or vehicle for 2 weeks under continued high-fat diet
Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues.2020PMID:33050029Permalink